Shashank Patel, MD
Pulmonary Disease · Norcross, GANPI 1598716995
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Novo Nordisk at 27.4% of the total. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 6 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$29
- AstraZeneca$27
- Rhythm Pharmaceuticals, Inc.$23
- Sanofi Pasteur Inc.$14
- Genentech USA, Inc.$12
Across 227 payments — averaging $1762.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rhythm Pharmaceuticals, Inc.$326K
- Chiesi USA, Inc.$32K
- Phathom Pharmaceuticals, Inc.$28K
- GSK$14K
What the payments were for
- Food & beverage$105100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 2 | $29 |
| AstraZeneca | 1 | $27 |
| Rhythm Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$105 in reported general payments places this provider in the 10th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $405 |
| Omeprazole | 14 | $188 |
| Gabapentin | 14 | $140 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $115 |
| Doxycycline Hyclate | 13 | $109 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $78 |
| Fluticasone Propionate | 11 | $60 |
| Ciprofloxacin Hcl | 12 | $41 |
| Potassium Chloride | 11 | $34 |
| Prednisone | 15 | $33 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Norcross
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
- Hitendra PatelMarietta$104K
- Eric FlenaughAtlanta$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.